

GENETIC ASSOCIATION ANALYSIS


SEQUENCE ANALYSIS WORKSHOP


HYUN MIN KANG





TODAY: GENETIC ASSOCIATION STUDIES





















A SINGLE MARKER ASSOCIATION TEST

- Simplest strategy to detect genetic association
- Compare frequencies of particular alleles, or genotypes, in set of cases and controls
- Typically, use contingency table tests...
 - Chi-squared Goodness-of-Fit Test
 - Cochran-Armitage Trend Test
 - Likelihood Ratio Test
 - Fisher's Exact Test
- ... or regression based tests.
 - More flexible modeling of covariates











GENOME-WIDE ASSOCIATION STUDIES





Sabatti et. al (2009)

TEST STATISTIC (FOR BALANCED CASE-CONTROL STUDIES)

$$z = \frac{\hat{p}_{+} - \hat{p}_{-}}{\sqrt{[\hat{p}_{+}(1-\hat{p}_{+}) + \hat{p}_{-}(1-\hat{p}_{-})]/(2N)}}$$

- \hat{p}_+ is observed case allele frequency
- \hat{p}_{-} is observed control allele frequency
- N is the number of cases and controls

DISTRIBUTION UNDER THE NULL

- Under the null hypothesis p₊ = p₋
- Z is distributed as Normal(0, 1) under the null
- Using Inverse Normal Cumulative Distribution Function
- Derive P-value thresholds for target significance level α

$$-\alpha$$
 = 0.05 leads to cutoff = $-\Phi^{-1}(0.05/2)=1.96$

$$-\alpha$$
 = 5x10⁻⁸ leads to cutoff = $-\Phi^{-1}(5\times10^{-8}/2)=5.45$

DISTRIBUTION UNDER THE ALTERNATIVE

- For a specific set of expected case and control allele frequencies..
- We can calculate the expected value of test statistic

$$\mu = \frac{p_{+} - p_{-}}{\sqrt{[p_{+}(1 - p_{+}) + p_{-}(1 - p_{-})]/(2N)}}$$

Under the alternative, statistic is Normal(µ,1)

POWER

- To calculate power, we first calculate:
 - Significance threshold C
 - Expected test statistic µ
- Use normal cumulative distribution function Φ

•
$$\Pr(|Z| > C) = \Pr(Z > C) + \Pr(Z < -C)$$

= $1 - \Phi(C - \mu) + \Phi(-C - \mu)$

Power calculation is important for designing association studies

Sources of Association

- Causal association
 - Genetic marker alleles influence susceptibility

best

- Linkage disequilibrium
 - Genetic marker alleles associated with other nearby alleles that influence susceptibility
- Population stratification
 - Genetic marker is unrelated to disease alleles

misleading

EXAMPLE OF SPURIOUS ASSOCIATION DUE TO POPULATION STRATIFICATION

	Population 1	Population 2	Combined
Allele Frequencies			
p_1	0.20	0.80	0.50
p ₂	0.80	0.20	0.50

Genotype Frequencies			
p ₁₁	0.04	0.64	0.34 (0.25 Expected)
p ₁₂	0.32	0.32	0.32 (0.50 Expected)
p ₂₂	0.64	0.04	0.40 (0.25 Expected)

EXAMPLE OF SPURIOUS ASSOCIATION DUE TO POPULATION STRATIFICATION

Population 1

	Allele 1	Allele 2
Affected	50	200
Unaffected	25	100

$$\chi^2 = 0.00$$
 p-value = 1.0

Population 2

	Allele 1	Allele 2
Affected	100	25
Unaffected	200	50

$$\chi^2 = 0.00$$
 p-value = 1.0

Combined

	Allele 1	Allele 2
Affected	150	225
Unaffected	225	150

$$\chi^2 = 29.2$$
 p-value = 6.5×10^{-8}


THE STRATIFICATION PROBLEM HAPPENS..


- If...
 - Phenotypes differ between populations
 - and allele frequencies have drifted apart
- Then..
 - Unlinked markers exhibit association
 - Not very useful for gene mapping!
- For example, Glaucoma has prevalence of ~2% in elderly Caucasians, but ~8% in African-Americans

POSSIBLE SOLUTIONS FOR POPULATION STRATIFICATION

- Avoid stratification by design
 - Collect a better matched sample by ancestry
 - Use family-based controls
 - and apply Transmission Disequilibrium Test (TDT)
- Analyze association by population groups
 - Using self reported ethnicity or genetic markers
 - Carry out association analysis within each group
- Account for inflated false-positive rate
 - Many different ways exist

GENOMIC CONTROL





Stratification → adjust test statistic
(Figure courtesy Shaun Purcell, Harvard, and Pak Sham, HKU)

DEFINE INFLATION FACTOR

- Compute chi-squared for each marker
- Inflation factor λ
 - Average observed chi-squared
 - Median observed chi-squared / 0.456
 - Should be >= 1
- Adjust statistic at candidate markers
 - Replace χ^2_{biased} with $\chi^2_{\text{fair}} = \chi^2_{\text{biased}}/\lambda$


QUESTIONS

- When defining the inflation factor λ ...
- Why do we use a lower bound of 1?
- What might be the advantages of using the median rather than the mean?

APPLYING GENOMIC CONTROL

- Simple and convenient approach...
 - Easily adapted to other test statistics, such as those for quantitative trait and haplotype tests
- Under the null, stratification always inflates evidence for association...
 - Is this also true under the alternative?
 - What might be the consequences?


Q-Q PLOTS: A USEFUL DIAGNOSTIC




The genomic control value examines markers with little evidence for association. If these large p-values were to deviate from expected, there is a problem! In this case, $\lambda=1.02$.

Willer et al, Nature Genetics, 2008

PRINCIPAL COMPONENTS MIRROR EUROPEAN GEOGRAPHY



CORRECTING FOR POPULATION STRUCTURE USING PRINCIPAL COMPONENTS



VARIANCE COMPONENT MODEL FOR FAMILY-BASED ASSOCIATION TEST

 Population-based analysis assumes uncorrelated phenotypes between individuals under the null

$$\mathbf{y} \sim \mathcal{N}(\mathbf{X}\beta, \sigma^2 I)$$

VARIANCE COMPONENT MODEL FOR FAMILY-BASED ASSOCIATION TEST

 Population-based analysis assumes uncorrelated phenotypes between individuals under the null

$$\mathbf{y} \sim \mathcal{N}(\mathbf{X}\beta, \sigma^2 I)$$

 Family-based analysis assumes phenotypes are correlated with relatives' phenotypes

$$\mathbf{y} \sim \mathcal{N}(\mathbf{X}\beta, \sigma_g^2 K + \sigma_e^2 I)$$
 κ_{ij} : kinship coefficient

VARIANCE COMPONENT MODEL FOR FAMILY-BASED ASSOCIATION TEST

 Population-based analysis assumes uncorrelated phenotypes between individuals under the null

$$\mathbf{y} \sim \mathcal{N}(\mathbf{X}\beta, \sigma^2 I)$$


 Family-based analysis assumes phenotypes are correlated with relatives' phenotypes

$$\mathbf{y} \sim \mathcal{N}(\mathbf{X}\beta, \sigma_g^2 K + \sigma_e^2 I)$$
 κ_{ij} : kinship coefficient

 Similar model for population-based analysis to account for distant relationship inferred from dense SNP arrays


$$\mathbf{y} \sim \mathcal{N}(\mathbf{X}\beta, \sigma_g^2 \hat{K} + \sigma_e^2 I)\,\hat{K}_{ij}$$
: marker-based kinship coefficient

GENOME-WIDE ASSOCIATION OF HUMAN HEIGHT



- NFBC 1966 birth cohort
 - Sabatti et al, Nat Genet (2008) 41:35-46
- Illumina 370,000 SNPs
- 5,326 unrelated individuals

UNCORRECTED ANALYSIS - OVERDISPERSION OF TEST STATISTICS -




$$\lambda_{GC} = \frac{\text{median}\{T_1, T_2, \cdots, T_n\}}{\mathbf{E}[\text{median}\{T\}]}$$

⁵Devlin & Roeder Biometrics (1999) 55:997-1004

YSIS WORKSHOP 2014

CONDITIONING ON PRINCIPAL COMPONENTS - OVERDISPERSION STILL EXISTS -



$$\mathbf{y} = \mu + \mathbf{x}\beta + G\gamma + \mathbf{e}$$

- ☐ G is top k(=100) eigenvectors of kinship matrix K
- \square λ_{GC} from 1.187 to 1.074
- lacksquare λ_{GC} is still substantially higher than expected
- Corrects for population structure, but not hidden relatedness


Price AL et al, Nat Genet (2006) 38:904-909

WORKSHOP 2014

37

VARIANCE COMPONENT MODEL

- OVERDISPERSION RESOLVED -




SUMMARY

- Genome-wide single variant test can identify regions of genome associated with disease traits
- Understanding power of your study design based on the genetic architecture of traits are important.
- Accounting for population structure and cryptic relatedness is important to avoid misleading results

RARE VARIANT BURDEN TESTS

BIOSTATISTICS 666
STATISTICAL METHODS IN HUMAN GENETICS

POWER TO DETECT VARIANTS FROM SEQUENCE DATA



WHY STUDY RARE VARIANTS?

COMPLETE GENETIC ARCHITECTURE OF EACH TRAIT

- Are there additional susceptibility loci to be found?
- What is the contribution of each identified locus to a trait?
 - Sequencing, imputation and new arrays describe variation more fully
 - Rare variants are plentiful and should identify new susceptibility loci

UNDERSTAND FUNCTION LINKING EACH LOCUS TO A TRAIT

- Do we have new targets for therapy?
 What happens in gene knockouts?
 - Use sequencing to find rare human "knockout" alleles
 - Good: Results may be more clear than for animal studies
 - Bad: Naturally occurring knockout alleles are extremely rare

WHY STUDY RARE VARIANTS?

COMPLETE GENETIC ARCHITECTURE OF EACH TRAIT

Coding Variants Especially Useful!

 Rare varia loci ntiful and should identify new susceptibility

UNDERSTAND FUNCTION LINKING EACH LOCUS TO A TRAIT

- Do we have new targets for therapy?
 What happens in gene knockouts?
 - Use sequencing to find rare human "knockout" alleles
 - Good: Results may be more clear than for animal studies
 - Bad: Naturally occurring knockout alleles are extremely rare

Lots of Rare Functional Variants to Discover

SET	# SNPs	Singletons	Doubletons	Tripletons	>3 Occurrences
Synonymous	270,263	128,319 (47%)	29,340 (11%)	13,129 (5%)	99,475 (37%)
Nonsynonymous	410,956	234,633 (57%)	46,740 (11%)	19,274 (5%)	110,309 (27%)
Nonsense	8,913	6,196 (70%)	926 (10%)	326 (4%)	1,465 (16%)
Non-Syn / Syn Ratio		1.8 to 1	1.6 to 1	1.4 to 1	1.1 to 1

There is a very large reservoir of extremely rare, likely functional, coding variants.

NHLBI Exome Sequencing Project

GENOME SCALE APPROACHES TO STUDY RARE VARIATION

- Deep whole genome sequencing
 - Can only be applied to limited numbers of samples
 - Most complete ascertainment of variation
- Exome capture and targeted sequencing
 - Can be applied to moderate numbers of samples
 - SNPs and indels in the most interesting 1% of the genome
- Low coverage whole genome sequencing
 - Can be applied to moderate numbers of samples
 - Very complete ascertainment of shared variation
- New Genotyping Arrays and/or Genotype Imputation
 - Examine low frequency coding variants in 100,000s of samples
 - Current catalogs include 97-98% of sites detectable by sequencing an individual

GENOME SCALE APPROACHES TO STUDY RARE VARIATION

- Deep whole genome sequencing
 - Can only be applied to limited numbers of samples
 - Most complete ascertainment of variation
- Exome capture and targeted sequencing
 - Can be applied to moderate numbers of samples
 - SNPs and indels in the most interesting 1% of the genome
- Low coverage
 - Ca
 - Ve

Our Focus For Today

- New Genotyping Arrays and or cenotype impacation
 - Examine low frequency coding variants in 100,000s of samples

me sequencing

Current catalogs include 97-98% of sites detectable by sequencing an individual

SNPs Per Individual

Primarily European Ancestry

European Ancestry	# SNP	# HET	# ALT	# Singletons	Ts/Tv
SILENT	10127	6174	3953	38.2	5.10
MISSENSE	8541	5184	3357	72.2	2.16
NONSENSE	86	57	29	2.1	1.70

Primarily African Ancestry

African Ancestry	# SNP	# HET	# ALT	# Singletons	Ts/Tv
SILENT	12028	8038	3990	53.2	5.19
MISSENSE	9870	6502	3367	94.2	2.16
NONSENSE	92	57	35	2.4	1.57

ASSOCIATION TEST OF SINGLE RARE VARIANT

- Consider variant with frequency of ~0.001
- Significance level of 5x10⁻⁶
 - Corresponds to ~100,000 independent tests
- Disease prevalence of ~10%
- Detecting a two-fold increase in risk, requires
 ~33,000 cases and ~33,000 controls!
- Detecting a three-fold increase in risk requires ~11,000 cases and ~11,000 controls!

RARE VARIANT ASSOCIATION TESTING

Consider variant with frequency of ~0.001

Power Depends Both On:

Frequency **Effect Size**

Even with large effects, rare variants

can only be detected in large samples

COLLAPSING RARE VARIANTS

- Instead of testing rare variants individually, group variants likely to have similar function
- Score presence or absence of rare variants per individual
 - Use rare variant score to predict trait values
- If all variants are causal, leads to large increase in power
- In practice, success depends on:
 - Number of associated variants,
 - Number of neutral variants diluting signals
 - Whether direction of effect is consistent within gene

BURDEN VS. SINGLE VARIANT TESTS

	Single Variant Test	Combined Test
10 variants / all have risk 2 / All have frequency .005	.05	.86
10 variants / all have risk 2 / Unequal Frequencies	.20	.85
10 variants / average risk is 2, but varies / frequency .005	.11	.97

- Power tabulated in collections of simulated data, for 250 cases and 250 controls
- Combining variants can greatly increase power
- Currently, appropriately combining variants is expected to be key feature of rare variant studies.

IMPACT OF NULL ALLELES

	Single Variant Test	Combined Test
10 disease associated variants	.05	.86
10 disease associated variants + 5 null variants	.04	.70
10 disease associated variants + 10 null variants	.03	.55
10 disease associated variants + 20 null variants	.03	.33

- Power tabulated in collections of simulated data
- Including non-disease variants reduces power
- Power loss is manageable, combined test remains preferable to single marker tests

IMPACT OF MISSING DISEASE ALLELES

	Single Variant Test	Combined Test
10 disease associated variants	.05	.86
10 disease associated variants, 2 missed	.05	.72
10 disease associated variants , 4 missed	.05	.52
10 disease associated variants , 6 missed	.04	.28
10 disease associated variants, 8 missed	.03	.08


- Power tabulated in collections of simulated data
- Missing disease associated variants loses power

EXOME SEQUENCING PROJECT

- The NHLBI Exome Sequencing Project is studying heart, lung and blood related traits
- One of the traits of interest is LDL, a major risk factor for cardiovascular disease
- Let's review their preliminary findings, in analysis of ...
 - 400 selected from top and bottom 2% of population
 - 1,600 individuals selected without consideration of LDL


LDL RESULTS - BURDEN TEST, MAF < 5%

(LOGISTIC REGRESSION ADJUSTED BY PCI, PC2, AGE, GENDER, CENTER)




LDL RESULTS – BURDEN TEST, MAF < 0.1%

(LOGISTIC REGRESSION ADJUSTED BY PCI, PC2, AGE, GENDER, CENTER)



LDL RESULTS – BURDEN TEST, MAF < 0.5%

(LOGISTIC REGRESSION ADJUSTED BY PCI, PC2, AGE, GENDER, CENTER)



Cristen Willer and Leslie Lange ANHLBI Exome Sequencing Project

VARIABLE THRESHOLD TESTS

- Different definitions of "rare" lead to different signals
- Conducting multiple analyses quickly becomes hard to manage
- What to do?
- Variable threshold tests consider all possible thresholds for each gene and search for maximum test statistic
 - Evaluate significance by permutation

VARIABLE THRESHOLD TESTS

- Price et al (2010) originally suggested using permutations for evaluating significance of variable threshold association tests
- Lin and Tang (2011) showed that statistics using different thresholds could be described using a multivariate normal distribution...
- ... allowing for p-value calculation without permutations.

ADDITIONAL COMPLICATIONS!

- What to do if a gene includes some rare alleles that increase risk, others that decrease it?
- What sort of signal do you expect?
- What sort of strategies might identify these signals?

ARTICLE

Extending Rare-Variant Testing Strategies: Analysis of Noncoding Sequence and Imputed Genotypes

Matthew Za ARTICLE and Sebastia

> **Pooled Association Tests for Rare Variants** in Exon-Resequencing Studies

Alkes L. Price, 1,2,3,6 Gregory V. Kryukov, 3,4,6 Paul I.W. de Bakker, 3,4 Shaun M. Purcell, 3,5 Jeff Staples, 3,4 Lee-Jen Wei,² and Shamil R. Sunyaev^{3,4,*} PLOS GENETICS

A Groupwise Association Test for Rare Mutations Using a **Weighted Sum Statistic**

Bo Eskerod Mac OPEN ACCESS Freely available online

PLOS COMPUTATIONAL BIOLOGY

A Covering Method for Detecting Genetic Associations between Rare Variants and Common Phenotypes

Gaurav Bhatia^{1,2}*, Vikas B_{OPEN} ACCESS Freely available online Vineet Bafna^{1,5}

PLOS GENETICS

A Novel Adaptive Method for the Analysis of Next-Generation Sequencing Data to Detect Complex Trait Associations with Rare Variants Due to Gene Main Effects and Interactions

Dajiang J. Liu^{1,2}, Suzanne M. Leal^{1,2}*

Analysing biological pathways in genome-wide association studies

Kai Wang**, Mingyao Li§ and Hakon Hakonarson*||

REVIEWS

Finding the missing heritability of complex diseases

Teri A. Manolio¹, Francis S. Collins², Nancy J. Cox³, David B. Goldstein⁴, Lucia A. Hindorff⁵, David J. Hunter⁶, Heri A. Malotiol, "Frairius S. Colinis, Naticy J. Cox, Davids D. Goldstein, E. Mark I. McCarthy", Erin M. Ranthum Genet (2010) 128:627–633

Augustine Kong¹¹, Leonid Krug (DOI 10.1007/s00439-010-0889-1

Alice S. Whittemore¹⁶, Michaell

Trudy F. C. Mackay²², Steven A

ORIGINAL INVESTIGATION

Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis

Gisela Oroze human genetics

doi: 10.1111/j.1469-1809.2010.00566.3

Common Susceptibility Variants Examined for Association with Dilated Cardiomyopathy

SUMMARY

- Analysis of individual rare variants requires very large samples.
- Power may be increased substantially by combining information across variants.
 - Strategy for combining information across variants allows for many tweaks.